Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE) — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
United States
Children's National Hospital, Washington D.C., District of Columbia Childrens National Hospital, Washington D.C., District of Columbia Age range
1 Year – 23 Years
Last updated January 2026